Clinical Trials Logo

Clinical Trial Summary

Many studies, including our own, have shown that colorectal cancer (CRC) is related to changes in the microbiome of the colon. However, there are limitations in most studies and questions remained unanswered. Some early data showing that the microbiome in the left vs right colon are different.

The aim of this study is to investigate the microbiome (including bacteriome, virome, and fungome) of adenoma/CRC comparing the left (distal to splenic flexure) vs right side (proximal to splenic flexure) of the colon.


Clinical Trial Description

1. Many studies, including our own, have shown that colorectal cancer (CRC) is related to changes in the microbiome of the colon

1. Certain bacterial phyla are more frequently presented in CRC

2. Bacterial diversity is reduced in CRC

3. Co-occurrence of bacterial phyla and exclusion are identified in CRC

4. Besides bacteriome, viromes have been found associated with CRC

5. These changes in the pattern may actually be used for diagnosis and prognosticate purposes.

2. However, there are limitations in most studies and questions remained unanswered

1. Most studies used stool sample and data of tissue (tumor and adjacent normal tissues) may not be available

2. Most studies take adenoma and CRC as one condition, without differentiating the findings according to tumor location

3. Most studies have separate bacteria, virus and fungi. There is a lack of data on their interaction

4. Most studies have identified either microbiome without correlating them with the genomic of the host

3. We know that not all CRC are the same. It has been known that rectal and colonic cancer are not the same. Furthermore, proximal (right) CRC and distal (left) CRC may not be the same.

1. Studies have shown compare to L-CRC, patients with R-CRC are older, more female (Iaocopetta B et al. Int J Cancer 2002)

2. Studies have also shown that the genomic make up of L-CRC and R-CRC are different. R-CRC are more likely to have family cancer syndrome (HNPCC), mostly diploid, less frequent to have loss heterozygosity, less TP53 mutations and more MSI and CIMP, and the gene expression are different (Glebov et al. Cancer Epi, Biomarker and Prevention 2003)

3. The response to therapy might also be different in the L-CRC compare to R-CRC

4. Recent studies show that the clinico-pathological and molecular features of early-onset (<50 years) CRC varies according to tumor location. (Peres J et al. Am J Cancer Res 2015). In the R-CRC in this group, germline mutation is more common (MLH1, MSH2, MSH6, PMS2 and EPCAM). Adenomas tend to be larger, flatter and more likely to have high-grade dysplasia and villous histology

5. Recent studies have also shown that the clinic-pathological and molecular feature of in the late-onset CRC (70-80 years) varies with tumor location (Brandariz et al. Oncotarget 2018). There are more sporadic MSI, more BRAF mutation and the adenoma/CRC are likely to be mucinous.

4. Studies comparing the microbiome of L-CRC vs R-CRC has not been many. There is some early data showing that the microbiome in the left vs right colon are different.

The aim of this study is to investigate the microbiome (including bacteriome, virome, and fungome) of adenoma/CRC comparing the left (distal to splenic flexure) vs right side (proximal to splenic flexure) of the colon. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03623152
Study type Observational
Source Chinese University of Hong Kong
Contact Yuet Ling Ching
Phone 35053524
Email jessicaching@cuhk.edu.hk
Status Recruiting
Phase
Start date August 7, 2018
Completion date October 6, 2019

See also
  Status Clinical Trial Phase
Recruiting NCT05074966 - The Efficacy and Safety of Modified XELOX(mXELOX) Plus Cetuximab vs FOLFOX Plus Cetuximab in RAS and BRAF WT mCRC Pts Phase 3
Active, not recruiting NCT03667716 - COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors. Phase 1
Suspended NCT05124743 - HLA Typing & Tumor Neoantigen Identification for Phase I/II Study of Autologous TCR-T Cells in Subjects With Solid Tumors
Recruiting NCT05056389 - Normothermic Intraperitoneal Chemotherapy - Long Term in Peritoneal Metastases From Colorectal Cancer (NIPEC-OXA) Phase 1
Completed NCT04551014 - Evaluation of EverLift in the Performance of Polypectomy for Polyps 4-9mm N/A
Completed NCT04551001 - Evaluation of Cold Forcep and Cold Snare Polypectomy for Polyps Less Than or Equal to 3mm in Size During Colonoscopy N/A
Recruiting NCT04270500 - The Impact of Physical Exercise on Sleep in Colorectal Cancer Patients During Prehabilitation Period N/A
Recruiting NCT03667911 - Virtual Reality Videos in Improving Bowel Preparation Quality of Colonoscopy N/A
Not yet recruiting NCT04073680 - A Phase 1b/2 Study of Serabelisib in Combination With Canagliflozin in Patients With Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT05572684 - A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants With Advanced Unresectable or Metastatic Solid Tumors Phase 1/Phase 2
Suspended NCT04108481 - Immunotherapy With Y90-RadioEmbolization for Metastatic Colorectal Cancer Phase 1/Phase 2
Completed NCT03567850 - Problem Solving Skills Training in Adult Cancer Survivors: Bright IDEAS-AC N/A
Recruiting NCT05870332 - Nationwide Study of Artificial Intelligence in Adenoma Detection for Colonoscopy
Completed NCT04534218 - Regorafenib in Combination With Metronomic Chemotherapies, and Low-dose Aspirin in Metastatic Colorectal Cancer Phase 2
Enrolling by invitation NCT05590117 - Protective Effect of Pentoxifylline Against Chemotherapy Induced Toxicities in Patients With Colorectal Cancer Early Phase 1
Recruiting NCT03129139 - A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Minnelideā„¢ Capsules Given Alone or in Combination With Protein-Bound Paclitaxel in Patients With Advanced Solid Tumors Phase 1
Completed NCT04195646 - Computer Aided Detection of Polyps During Colonoscopy Procedures N/A
Not yet recruiting NCT03261752 - New Genes in the Carcinogenesis of Colorectal Cancer
Not yet recruiting NCT03618329 - Effect of Prehabilitation on the Lean Mass Index (IMM) in ERAS PROGRAMM. N/A
Terminated NCT03621982 - Study of ADCT-301 in Patients With Selected Advanced Solid Tumors Phase 1